New drugs in prostate cancer

@inproceedings{Yoo2016NewDI,
  title={New drugs in prostate cancer},
  author={Sangjun Yoo and Se Young Choi and Dalsan You and Choung Soo Kim},
  booktitle={Prostate international},
  year={2016}
}
The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 6 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 46 REFERENCES

Similar Papers

Loading similar papers…